Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

2,243 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Genetic variability in DNA repair and cell cycle control pathway genes and risk of smoking-related lung cancer.
Buch SC, Diergaarde B, Nukui T, Day RS, Siegfried JM, Romkes M, Weissfeld JL. Buch SC, et al. Among authors: day rs. Mol Carcinog. 2012 Oct;51 Suppl 1(Suppl 1):E11-20. doi: 10.1002/mc.20858. Epub 2011 Oct 4. Mol Carcinog. 2012. PMID: 21976407 Free PMC article.
Calculation of lytic units for the expression of cell-mediated cytotoxicity.
Bryant J, Day R, Whiteside TL, Herberman RB. Bryant J, et al. Among authors: day r. J Immunol Methods. 1992 Jan 21;146(1):91-103. doi: 10.1016/0022-1759(92)90052-u. J Immunol Methods. 1992. PMID: 1735786
Long-term tamoxifen citrate use and potential ocular toxicity.
Gorin MB, Day R, Costantino JP, Fisher B, Redmond CK, Wickerham L, Gomolin JE, Margolese RG, Mathen MK, Bowman DM, Kaufman DI, Dimitrov NV, Singerman LJ, Bornstein R, Wolmark N. Gorin MB, et al. Among authors: day r. Am J Ophthalmol. 1998 Apr;125(4):493-501. doi: 10.1016/s0002-9394(99)80190-1. Am J Ophthalmol. 1998. PMID: 9559735 Clinical Trial.
METHODS: A single-masked, cross-sectional study involving multiple community and institutional ophthalmologic departments was conducted with a volunteer sample of 303 women with breast cancer currently taking part in a randomized clinical trial to determine the efficacy of tamoxi …
METHODS: A single-masked, cross-sectional study involving multiple community and institutional ophthalmologic departments was conducted with …
A phase II trial of all-trans-retinoic acid in hormone-refractory prostate cancer: a clinical trial with detailed pharmacokinetic analysis.
Trump DL, Smith DC, Stiff D, Adedoyin A, Day R, Bahnson RR, Hofacker J, Branch RA. Trump DL, et al. Among authors: day r. Cancer Chemother Pharmacol. 1997;39(4):349-56. doi: 10.1007/s002800050582. Cancer Chemother Pharmacol. 1997. PMID: 9025776 Clinical Trial.
The pharmacokinetics of ATRA were assessed with the first dose on day 1, again on day 14 and after a 7-day interruption in ATRA therapy on day 22. ...Apparent clearance of ATRA changed substantially during therapy: day 1 3779 +/- 4215 ml/min, …
The pharmacokinetics of ATRA were assessed with the first dose on day 1, again on day 14 and after a 7-day interruption …
Sharing detailed research data is associated with increased citation rate.
Piwowar HA, Day RS, Fridsma DB. Piwowar HA, et al. Among authors: day rs. PLoS One. 2007 Mar 21;2(3):e308. doi: 10.1371/journal.pone.0000308. PLoS One. 2007. PMID: 17375194 Free PMC article.
Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial.
Ernstoff MS, Gooding W, Nair S, Bahnson RR, Miketic LM, Banner B, Day R, Whiteside T, Titus-Ernstoff L, Kirkwood JM. Ernstoff MS, et al. Among authors: day r. Cancer Res. 1992 Feb 15;52(4):851-6. Cancer Res. 1992. PMID: 1737346 Clinical Trial.
This report details a prospective study of the immunological effects on peripheral blood mononuclear cells of sequentially administered recombinant (r) interferon (IFN) gamma and rIFN alpha in 28 patients with metastatic renal cell carcinoma. ...
This report details a prospective study of the immunological effects on peripheral blood mononuclear cells of sequentially administered reco …
2,243 results
Jump to page
Feedback